The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Carl Borrebaeck

Carl Borrebaeck

Professor

Carl Borrebaeck

GARD : Genomic allergen rapid detection

Author

  • Malin Lindstedt
  • Kathrin Stephanie Zeller
  • Henrik Johansson
  • Carl Borrebaeck

Summary, in English

Genomic allergen rapid detection (GARD) is an in vitro assay for the prediction of skin sensitizing capacity of chemicals. The GARD assay monitors changes in the expression of 196 genes, termed the GARD prediction signature. In short, MUTZ-3 cells, representing a well-characterized in vitro model of human dendritic cells (DCs), are exposed to the test substances for 24 h. After RNA extraction and analysis of expression levels, compounds are predicted as either sensitizers or non-sensitizers by a support vector machine model. Due to high information content, the test can deliver novel insights into pathway utilization and potency. Based on blinded test evaluations, GARD has been shown to have an accuracy of 89%.

Department/s

  • Department of Immunotechnology
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation

Publishing year

2017

Language

English

Pages

393-403

Publication/Series

Alternatives for Dermal Toxicity Testing

Document type

Book chapter

Publisher

Springer International Publishing

Topic

  • Pharmacology and Toxicology

Keywords

  • Biomarker signatures
  • Dendritic cells
  • Human
  • In vitro assay
  • Sensitization

Status

Published

ISBN/ISSN/Other

  • ISBN: 9783319503516
  • ISBN: 9783319503530